A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Forced-dose Titration Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Binge Eating Disorder

Trial Profile

A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Forced-dose Titration Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Binge Eating Disorder

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2015

At a glance

  • Drugs Lisdexamfetamine (Primary)
  • Indications Binge-Eating Disorder
  • Focus Therapeutic Use
  • Sponsors Shire
  • Most Recent Events

    • 17 May 2013 Data will be presented at the American Psychiatric Association (APA) 166th Annual Meeting, according to a Shire media release.
    • 06 Aug 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top